BHCM
REGN icon

Brevan Howard Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brevan Howard Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Sell
334
-19,651
-98% -$15M ﹤0.01% 1726
2025
Q4 		$15.4M Buy
19,985
+14,745
+281% +$10M 0.17% 80
2025
Q3 		$2.95M Sell
5,240
-1,442
-22% -$815K 0.01% 412
2025
Q2 		$3.51M Sell
6,682
-657
-9% -$367K 0.02% 508
2025
Q1 		$4.65M Sell
7,339
-351
-5% -$241K 0.04% 145
2024
Q4 		$5.48M Buy
7,690
+4,506
+142% +$3.78M 0.04% 135
2024
Q3 		$3.35M Buy
+3,184
New +$3.54M 0.02% 174
2024
Q2 		– Sell
-3,106
Closed -$2.99M – 1347
2024
Q1 		$2.99M Buy
3,106
+1,943
+167% +$1.85M 0.03% 107
2023
Q4 		$1.02M Buy
+1,163
New +$958K 0.01% 229

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Brevan Howard Capital Management's REGN Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 98% in Q1 2026, selling an estimated $15M and leaving 334 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Brevan Howard Capital Management first reported a position in REGN in Q4 2023 and has held it in 9 quarters since. The position peaked at $15.4M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Brevan Howard Capital Management held 334 shares of Regeneron Pharmaceuticals worth $258K as of Q1 2026.
  • Brevan Howard Capital Management sold 19,651 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $15M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1726 holding.
  • Brevan Howard Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Brevan Howard Capital Management's Regeneron Pharmaceuticals position peaked at $15.4M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.